Telaglenastat Hydrochloride

Phase 1Small molecule

Telaglenastat Hydrochloride is one of 83 small molecule programs targeting Anaplastic Astrocytoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anaplastic AstrocytomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Anaplastic AstrocytomaPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

Lenvima

Eisai

Preclinical

6 3

Imjudo

AstraZeneca

Preclinical

5 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT04250545

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT03831932·22 enrolled

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04250545·22 enrolled

Treatment1 trial

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03872427·54 enrolled

Multiple Myeloma1 trial

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03798678·36 enrolled

Anaplastic Astrocytoma1 trial

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03528642·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Telaglenastat Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telaglenastat Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Telaglenastat Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Telaglenastat Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Treatment1 trial

Multiple Myeloma1 trial

Anaplastic Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News